Ferring finds a new approach to communicate its value offering
The new, stronger roles of payer bodies in the system have led to various restructurings at the affiliate level for pharmaceutical companies, often for the better, in order to revamp their communication strategies with stakeholders. Ferring, the 60-year old Swiss biopharmaceutical specialist in reproductive health, urology, gastroenterology, and endocrinology, found that a whole new approach was needed in order to communicate its value offering to the "new kid on the block." Anita Goedknegt, general manager, explains that "prior to 2006 pharmaceutical companies had a large group of sales representatives or account managers who were predominantly focused on the prescribers. The prescribers were the decision-makers with whom you needed to be in constant contact. After the policy change it was no longer just the doctor in charge. We as an organization needed to change everything—and I mean everything."
Human resource changes were necessary in order to align Ferring's structure, processes, and organizational attributes with evolving market needs. "Our growth was driven by a stronger connection between the organization and the market environment," she explains. Growth and results for that matter have been extraordinary for Ferring since 2006, despite not introducing new products to the Dutch market until 2009. "Up to 2006, we were in a stable annual growth scenario. In that year we changed the entire organization, including its structure and quite some processes, which altogether created a 'hockey stick growth' for our affiliate." Operating in niche markets of fertility, obstetrics, and inflammatory disease, Ferring has consistently relied on double-digit growth in volume, and is projecting similar success for 2011.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.